Zevra Therapeutics (NASDAQ:ZVRA) Director Sells $138,375.00 in Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Director Corey Michael Watton sold 12,300 shares of Zevra Therapeutics stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $11.25, for a total value of $138,375.00. Following the sale, the director directly owned 1,800 shares in the company, valued at $20,250. The trade was a 87.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Zevra Therapeutics Trading Up 1.3%

Shares of NASDAQ ZVRA opened at $11.32 on Friday. The business has a fifty day simple moving average of $12.35 and a 200 day simple moving average of $10.66. The firm has a market capitalization of $672.18 million, a price-to-earnings ratio of 12.30 and a beta of 0.91. Zevra Therapeutics, Inc. has a one year low of $7.16 and a one year high of $15.03.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its earnings results on Wednesday, August 5th. The company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.11 by $0.14. The firm had revenue of $39.66 million during the quarter, compared to analysts’ expectations of $33.88 million. Zevra Therapeutics had a return on equity of 54.54% and a net margin of 42.82%. On average, research analysts anticipate that Zevra Therapeutics, Inc. will post 0.6 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on ZVRA. Canaccord Genuity Group decreased their target price on shares of Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating on the stock in a research report on Monday, July 27th. Weiss Ratings lowered shares of Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research report on Friday, May 22nd. Cantor Fitzgerald raised their price target on shares of Zevra Therapeutics from $24.00 to $34.00 and gave the stock an “overweight” rating in a research note on Monday, June 8th. HC Wainwright restated a “buy” rating and set a $26.00 price target on shares of Zevra Therapeutics in a research note on Tuesday, June 23rd. Finally, Guggenheim decreased their price objective on Zevra Therapeutics from $24.00 to $23.00 and set a “buy” rating on the stock in a report on Friday, August 7th. Nine equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $27.14.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in ZVRA. AIGH Capital Management LLC bought a new stake in shares of Zevra Therapeutics in the 1st quarter worth about $11,184,000. Dimensional Fund Advisors LP increased its position in shares of Zevra Therapeutics by 259.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 554,802 shares of the company’s stock worth $5,168,000 after purchasing an additional 400,336 shares in the last quarter. Hennion & Walsh Asset Management Inc. lifted its holdings in Zevra Therapeutics by 116.6% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 383,706 shares of the company’s stock valued at $5,502,000 after purchasing an additional 206,543 shares during the last quarter. UBS Group AG lifted its holdings in Zevra Therapeutics by 30.9% during the 4th quarter. UBS Group AG now owns 285,488 shares of the company’s stock valued at $2,558,000 after purchasing an additional 67,392 shares during the last quarter. Finally, Retirement Planning Co of New England Inc. lifted its holdings in Zevra Therapeutics by 10.4% during the 4th quarter. Retirement Planning Co of New England Inc. now owns 662,976 shares of the company’s stock valued at $5,940,000 after purchasing an additional 62,206 shares during the last quarter. 35.03% of the stock is owned by institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.